Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt(Institute of Cancer Research), Holly Tovey(Institute of Cancer Research), Maggie C.U. Cheang(Institute of Cancer Research), Sarah Kernaghan(Institute of Cancer Research), Lucy Kilburn(Institute of Cancer Research), Patrycja Gazińska(Guy's Hospital), Julie Owen(King's College London), Jacinta Abraham(Velindre Cancer Centre), Sophie Barrett(Beatson West of Scotland Cancer Centre), Peter Barrett‐Lee(Velindre Cancer Centre), Robert Brown(Institute of Cancer Research), Stephen Chan(Nottingham University Hospitals NHS Trust), Mitch Dowsett(Institute of Cancer Research), James M. Flanagan(Imperial College London), Lisa Fox(Institute of Cancer Research), Anita Grigoriadis(Guy's Hospital), Alexander Gutin(Myriad Genetics), Catherine Harper‐Wynne(Maidstone and Tunbridge Wells NHS Trust), M. Hatton(Weston Park Cancer Centre), Katherine A. Hoadley(University of North Carolina at Chapel Hill), Jyoti Parikh(St Thomas' Hospital), Peter J. Parker(King's College London), Charles M. Perou(University of North Carolina at Chapel Hill), Rebecca Roylance(UCL Biomedical Research Centre), Vandna Shah(Guy's Hospital), Adam Shaw(Guy's and St Thomas' NHS Foundation Trust), Ian E. Smith(Royal Marsden NHS Foundation Trust), Kirsten M. Timms(Myriad Genetics), Andrew Wardley(Manchester Academic Health Science Centre), G. Wilson(The Christie NHS Foundation Trust), Cheryl Gillett(Guy's Hospital), Jerry S. Lanchbury(Myriad Genetics), Alan Ashworth(University of California, San Francisco), Nazneen Rahman(Royal Marsden NHS Foundation Trust), Mark Harries(Guy's and St Thomas' NHS Foundation Trust), Paul Ellis(Guy's and St Thomas' NHS Foundation Trust), Sarah E. Pinder(Guy's Hospital), Judith M. Bliss(Institute of Cancer Research)
Cited by 899Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis